Results 51 to 60 of about 4,783,354 (355)

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano, Alexander Yelak, Walid Kaadan, Shlomo Caduri, Rivka Friedland, Orli Michaeli, Gad Dotan, Osnat Konen   +7 more
wiley   +1 more source

Cognitive Functioning in Vorinostat‐Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Cognitive and psychological difficulties could negatively interfere with treatment adherence and quality of life before and after hematopoietic stem cell transplant (HSCT). Methods to mitigate these changes may have positive effects on treatment success.
Kristen L. Votruba, Michelle Rozwadowski, Thomas Braun, April Rahrig, Edward Peres, Kirsten M. Williams, Vanessa Fabrizio, Julie‐An Talano, Carrie L. Kitko, Nicolas Parnell, Pavan Reddy, Sung Won Choi   +11 more
wiley   +1 more source

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited [PDF]

, 2012
The cellular and molecular mechanisms of tumor angiogenesis and its prospects for anti-angiogenic cancer therapy are major issues in almost all current concepts of both cancer biology and targeted cancer therapy. Currently, (1) sprouting angiogenesis, (2)
Dumont, Daniel J., Plate, Karl H., Scholz, Alexander   +2 more
core   +1 more source

Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis

International Journal of Molecular Sciences, 2021
Amyotrophic Lateral Sclerosis (ALS) is the most common degenerative motor neuron disease in adults. About 97% of ALS patients present TDP-43 aggregates with post-translational modifications, such as hyperphosphorylation, in the cytoplasm of affected ...
Loreto Martínez-González, Claudia Gonzalo-Consuegra, Marta Gómez-Almería, Gracia Porras, Eva de Lago, Á. Martín-Requero, Ana Martínez   +6 more
semanticscholar   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh   +10 more
wiley   +1 more source

Triafamone (AE 1887196) a new rice herbicide for Asia

Julius-Kühn-Archiv, 2012
Triafamone (approved ISO common name) is a new sulfonanilide herbicide discovered and developed by Bayer CropScience AG under the code number AE 1887196. Its mode of action is inhibition of the enzyme acetolactate synthase (ALS).
Sato, Yoshitaka, Hacker, Erwin, Shirakura, Shinichi, Rosinger, Christopher, Heibkes, Silke, Nakamura Shin   +5 more
doaj   +1 more source

First Report of Multiple Resistance in Galium aparine to ALS-Inhibiting and Auxin Analog Herbicides in Kermanshah, Iran [PDF]

Planta Daninha, 2019
: Catchweed Bedstraw (Galium aparine) is a problematic weed, which has become increasingly difficult to control with herbicides in Iran. The aim of this study was to screen selected putative-resistant populations of G.
I. NOSRATTI, A. MUHAMMADYARI
doaj   +1 more source

Proteasome Inhibitors to Treat AL Amyloidosis

, 2016
Amyloidoses represent a highly heterogeneous group of diseases characterized by the abnormal production and accumulation of abnormal, insoluble amyloid proteins in various tissues leading to organ dysfunction. Light‐chain (AL) amyloidosis is the most common form of systemic amyloidosis and is characterized by extracellular deposi‐ tion of pathologic ...
Driscoll, James J., Girnius, Saulius
openaire   +3 more sources

Intraoperative Collection of Ascitic Fluid With Intra‐ or Postoperative Reinfusion in Ovarian Cancer: Safety and Feasibility of a Roller Pumping Method

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Patients with ovarian cancer often present with massive ascites, leading to significant protein loss during surgical procedures. Although cell‐free concentrated ascites reinfusion therapy (CART) is used in palliative settings to mitigate protein loss, its application in intraoperative settings remains unexplored.
Yutaka Yoneoka, Tsukuru Amano, Akimasa Takahashi, Mari Deguchi, Hiroyuki Yamanaka, Yuji Tanaka, Shunichiro Tsuji, Takashi Murakami   +7 more
wiley   +1 more source